Next Phase Newsletter

A hybrid venture capital and hedge fund is managed by a firm based in the Western United States. The firm is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture fund formed by a group of high net-worth individuals in China is currently seeking investment opportunities globally with a focus on China and US. Projects based in Canada, Germany, and Switzerland may also be considered. The fund pays close attention to investment opportunities from seed and early stage to growth stage. For seed and early stage projects, the fund makes investments in convertible notes and equity and is flexible on investment size. For growth stage projects, the fund makes equity investments of US$1-5 million in businesses with valuation of up to US$18-20 million. The fund typically syndicates with co-investors. The fund would like to partner with local investors in case of overseas investments.

The fund focuses on high-growth fields in medical devices, diagnostics, digital health, and consumer products and is agnostic to therapeutic areas. In diagnostics, the fund is interested in portable imaging devices, high-intensity ultrasound, point-of-care diagnostics, and molecular diagnostics. In digital health, the fund is interested in technologies that can be applicable to the Chinese market, such as connected devices, telemedicine, and patient-physician platforms. In consumer products, the fund in interested in OTC, nutrition, and dietary supplements that have proven efficacy and are on market.

The fund is looking to work with serial entrepreneurs from seed and early stages to growth stage to form complete and strong teams. The fund typically cooperates with local co-investors who play a supervisory role in overseas operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A European VC firm with over €700 million in total assets under management, and has raised a total of five funds; the most recent fund closed in 2014. The firm typically invests €1-5 million in venture-stage opportunities, or up to €15 million in growth-stage opportunities. The firm is open to opportunities globally and has invested in Western and Eastern Europe, the Middle East and the USA.

Within the life science sector the firm is currently focused on medical technology, diagnostics, life science tools, and digital health. The firm is open to all classes of devices and molecules, is open to opportunities in any indication area and at any phase of development. Previous investments include diagnostics for stroke, Nano coatings for implants, and cardiovascular catheters.

The firm is open to investing in pre-revenue companies, companies at the early commercialization stage, as well companies generating steady revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2012 with offices in Eastern and Western US and Ireland is currently looking to make new investments into biopharmaceutical and medical device companies from its $172 million fund. The firm looks to invest in companies in seed to series B rounds and can provide up to about $17 million to a company over the lifetime of the investment. The firm is most interested in companies based in the US, Canada, and Ireland and will also consider exceptional opportunities elsewhere in Europe and in Asia. The firm plans to make approximately 4-5 new investments over the next 6-9 months.

The firm is interested in companies developing either biopharmaceuticals or medical devices. For biopharmaceuticals, the firm is interested in all modalities including small molecules, biologics, and cell and gene therapies. The firm is primarily interested in platform companies with the potential for multiple assets and strongly prefers technologies to be 1^st in class or best in class, often originating from breakthrough chemistry or biology discoveries. The firm is looking for companies with assets in preclinical development through Phase 1 clinical trials. For medical devices, the firm is primarily interested in companies working on devices that are therapeutic in nature, as well as devices for self-pay markets, including aesthetics. The firm is indication-agnostic in both biopharmaceuticals and devices.

The firm can both lead and co-lead investments, with a preference for taking a board seat. The firm prefers working with management teams with positive track records; however, they are open to working with incomplete or non-permanent management teams as well, especially for very early stage opportunities. The firm’s team has extensive operating experience and deep networks, which they can leverage to support companies as needed.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A big pharmaceutical corporation based in Western Europe with offices worldwide forms partnerships with early-stage biotech companies. The firm also invests via a venture arm, which is highly strategic in nature; the firm shares access to opportunities with the fund. The firm invests in technologies from an early discovery stage onwards, and partners with companies worldwide.

The firm’s therapeutic areas are Oncology & Cancer Immunotherapy, Ophthalmology, Immunology, Infectious Disease & Specialty Care, and Neuroscience. In the oncology sector, the firm seeks assets that have a biomarker hypothesis that can be used to select and stratify patient populations; in addition to therapeutic assets, biomarker diagnostics are also of interest. In Ophthalmology, the firm focuses on ‘back of the eye’ diseases such as AMD, diabetic retinopathy, and diabetic macular edema, and is also interested in other eye diseases such as retinitis of prematurity, retinitis pigmentosa, uveitis, dry eye, and glaucoma. In immunology/infectious disease, the firm focuses on hepatitis B, influenza and antibacterials; the firm is also interested in respiratory infections, HPV and HIV. In neurology, the firm focuses on neurodegenerative diseases (Alzheimer’s, Parkinson’s), schizophrenia, multiple sclerosis, depression, and autism spectrum disorders. Opportunities from the lead op stage onwards are evaluated by the firm’s therapeutic area groups.

The firm is interested in companies that align with the firm’s areas of focus and which have attained proof of principle or proof of concept data for their asset, and prefers that assets have obtained robust preclinical data across several species. Evidence of target engagement is of importance. In oncology assets, the possibility of combinability with the firm’s asset is also of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture-capital firm supports early stage companies in the Mid-Atlantic Region – Maryland, Virginia, Washington, DC, and North Carolina. The firm makes approximately 6 investments per year into companies seeking investment rounds less than $4m. During a single round, the firm will typically make an equity investment of $500k to $1.0m. For companies that require larger financing rounds, the firm will look to syndicate deals with other investment groups in their network.

The firm is interested in medical devices (class 1 or 2) and healthcare IT opportunities. The firm looks for companies already generating revenues or close, within 12-18 months of doing so. Within medical devices, the firm requires FDA clearance or close to doing so. The firm is open to all indication areas.

The firm looks for a strong, proven leadership team with a clear path and desire to exit, unique value proposition, competitive term sheet and interest in investors who can provide value beyond the checkbook.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist healthcare company with offices in Europe, North America, and Australia, is looking to in-license and acquire therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 and more for later stage acquisitions. The firm is primarily interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in Therapeutic assets and Medical Devices. For therapeutics the firm’s current products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. The firm is open to therapeutics within these areas as well as other indications pending they are intended to be hospital products. The firm primarily focuses on small molecule therapeutics. For medical devices the firm is looking for companies that have 510 K approval in Oncology, Vascular and Pulmonary fields. The firm’s current device products include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots.

The firm is interested in working with founding management teams prior to investment and is open to in-license from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com